1. Introduction {#s0005}
===============

The classic paradigm for vitamin D production and metabolism in which vitamin D is made in the skin, converted to its major circulating form 25hydroxy vitamin D (25OHD) in the liver, and to 1,25 dihydroxyvitamin D (1,25(OH)~2~D) in the kidney has undergone major revisions with the findings that cells other than epidermal keratinocytes have the capability of producing vitamin D following UVB exposure ([@bb0995]), that several 25OHD hydroxylases exist and not only in the liver ([@bb0520]), and that numerous tissues other than the kidney produce 1,25(OH)~2~D, the subject of this review. When Fraser and Kodicek ([@bb0390]) first identified the kidney as the source of 1,25(OH)~2~D in 1971~,~ it was originally thought to be the sole source. Indeed two studies examining the conversion of radiolabeled 25OHD to 1,25(OH)~2~D in anephric rats failed to detect any formation of 1,25(OH)~2~D ([@bb0795]; [@bb0880]). However, when anephric rats are pregnant, 1,25(OH)2D is produced ([@bb0460]). Similarly a case report of a woman with chronic kidney disease who showed an increase in 1,25(OH)~2~D when pregnant was published ([@bb0975]), and the human placenta was shown to be capable of 1,25(OH)2D production ([@bb1020]). Moreover, studies in anephric humans ([@bb0595]; [@bb0315]) and pigs ([@bb0650]) that were not pregnant found detectable levels of 1,25(OH)~2~D at baseline that could be further increased with 25OHD or vitamin D administration. A report by Barbour et al. ([@bb0095]) of an anephric patient with sarcoidosis with clearly detectable 1,25(OH)~2~D levels demonstrated a disease state in which extra renal 1,25(OH)~2~D~3~ production occurred. The source was soon discovered to be the activated pulmonary alveolar macrophages from the involved lungs ([@bb0020]). At about the same time, a number of investigators were finding 1,25(OH)~2~D production by bone cells ([@bb0970]), melanocytes ([@bb0385]), and epidermal keratinocytes in vitro ([@bb0145]) and in vivo ([@bb0170]). With the cloning of the 25OHD 1α hydroxylase (CYP27b1) in 1997 by 4 groups ([@bb0415]; [@bb0945]; [@bb0900]; [@bb0875]) came the demonstration that the extrarenal CYP27b1 was the same as the renal CYP27b1 ([@bb0415]; [@bb0515]). Moreover, the mutations in CYP27b1 that led to pseudo vitamin D deficiency resulted in absent CYP27b1 activity in the skin ([@bb0415]) and placenta. The cloning also enabled the development of molecular probes and antibodies to CYP27b1 ([@bb1045]; [@bb1050]) facilitating the demonstration of its expression in many other tissues. It soon became apparent that the regulation of CYP27b1 activity in non-renal tissues differed from that in the kidney. This difference in regulation is clearly demonstrated in diseases such as sarcoidosis and other disorders that lead to unregulated increases in circulating 1,25(OH)~2~D and hypercalcemia as illustrated by the case report of a B cell lymphoma presenting with hypercalcemia that initiates this review. Thus the demonstration of CYP27b1 in tissues that were not obviously involved in bone mineral metabolism but which also expressed the vitamin D receptor raised the question of its physiologic role in these extrarenal sites. This question has started to be addressed with the development of a mouse model in which CYP27b1 has been deleted ([@bb0750]; [@bb0265]), and more specifically a mouse model in which CYP27b1 can be deleted in a tissue specific fashion ([@bb0905]). This chapter will address the tissue distribution of CYP27b1, the regulation of CYP27b1 in these cells, and the potential significance of these extra renal locations in health and disease.

2. Case report {#s0010}
==============

A 74 year old male with a past medical history of prostate cancer status-post radical prostatectomy presented to the Emergency Department with flank pain in 12/2015. Work up included a CT scan of the abdomen and pelvis, which showed multiple new lytic pelvic and spinal lesions as well as diffuse lymphadenopathy of unclear etiology. About two weeks later, he presented with acute right arm pain that started after he was getting out of a car. He was found to have a mid-shaft humeral fracture and was admitted to the hospital for further work-up and management. During this admission, a PET/CT (positron emission tomography/computed tomography) showed progression of disease also now involving the liver and spleen. About 1 week into this hospital admission, he developed acute bilateral lower extremity weakness. MRI of the spine showed T11 vertebral body compression and extension of tumor into the anterior epidural space causing cord compression. He underwent urgent decompressive laminectomy, and pathology from this resection revealed high grade B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Chemotherapy was initiated, and he received 2 cycles of R-EPOCH (rituximab in combination with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and intrathecal methotrexate. On the first day of chemotherapy, his corrected calcium was 12.8, PTH 1.1 pg/ml (ref 15--88 pg/mL), PTH-related peptide 13 pg/ml (ref 14--27 pg/ml), and 25-hydroxyvitamin D 21.8 ng/ml (ref 25--50 ng/mL). 1,25-dihydroxyvitamin D was not measured at the time. Zometa was recommended by Oncology for treatment of pathological fractures. Over the next five months, he completed four additional cycles of R-EPOCH and one additional dose of Zometa. Repeat PET/CT showed continued progression of lymphoma. About three months following last cycle of chemotherapy (9/2016), he was admitted for altered mental status. He was residing in a skilled nursing facility and was noted to be more confused. Labs were notable for corrected calcium of 16.6 mg/dL. He received intravenous fluids, calcitonin and Zometa, both of which were given to reduce the contribution of bone resorption to the hypercalcemia. He was not taking vitamin D or calcium supplements. The following day his corrected calcium improved to 13.6 mg/dL. Other labs were notable for creatinine 0.8 mg/dL, phosphorus 2.6 mg/dL (ref 2.5--4.5 mg/dL), PTH 2.9 pg/ml (ref 15--88 pg/ml), PTH-related peptide 16 pg/ml (ref 14--27 pg/ml), alkaline phosphatase 84 U/L (ref 40--125 U/L), TSH 1.80 uU/mL (ref 0.4--6 uU/mL), 25-hydroxyvitamin D 25 ng/mL (ref 25--50 pg/ml). Subsequent immunohistochemical staining for 1 alpha hydroxylase (CYP27B1) in surgical tissue from the T11 mass resection was strongly positive both for the lymphoma and the adjacent osteoblasts and osteoclasts ([Fig. 1](#f0005){ref-type="fig"}). The etiology of the hypercalcemia was clearly related to the elevated 1,25-dihydroxyvitamin D production from the tumor, although the PTHrP was also not suppressed and was possibly playing a role. About 1.5 weeks into his hospitalization, the patient received palliative chemotherapy with rituximab, gemcitabine and oxaliplatin (R-Gem-Ox). He received a total of 2 cycles. He was also started on prednisone to reduce the burden of cells overproducing 1,25(OH)~2~D. A lower dose of 20 mg daily was chosen due to concerns of immunosuppression with concurrent chemotherapy. Two weeks into steroid therapy and after another dose of Zometa, his prednisone was increased to 40 mg daily given he continued to have hypercalcemia as well as elevated 1,25(OH)~2~D (82 pg/mL). One month into steroid therapy, he developed muscle weakness, concerning for steroid myopathy, and his prednisone was tapered back down to 20 mg daily with plans to completely taper off. However, his calcium was starting to increase again, so prednisone was increased back to 40 mg daily. A follow-up PET/CT confirmed no response to chemotherapy ([Fig. 2](#f0010){ref-type="fig"}). The patient was also experiencing functional and cognitive decline, prompting transition to hospice. He expired on December 14, 2016. His hospital course is shown in [Fig. 3](#f0015){ref-type="fig"} with respect to serum calcium levels.Fig. 1Increased expression of CYP27B1 in the infiltrating tumor and osteoblasts, osteocytes, and osteoclasts of adjacent bone. The upper panels show the tumor, with H&E staining on the left and a serial section immunostained for CYP27b1 on the right. The expression of CYP27b1 is depicted by the brown color. The lower panels demonstrate the strong staining for CYP27b1 in the osteoblasts lining the bone (lower left panel), osteocytes close to the surface of bone (lower left panel), and osteoclasts (arrow in lower right panel). The 20× bar = 50 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1Fig. 2Whole body PET/CT. These show the results after 6 cycles of R-EPOCH on the left and 2 cycles of R-GEM-OX on the right. The black regions show the increased uptake of the fluordeoxyglucose used as the tracer for the PET/CT studies that signify the increased metabolic activity of the tumor.Fig. 2Fig. 3Hospital course of the patient. The upper limits of calcium in this hospital are 10.5 mg/dl. Levels above 13 mg/dl are generally associated with altered mental status to coma and require emergency treatment as in this case.Fig. 3

Although this review will emphasize the physiologic role of extra renal CYP27b1, this case report emphasizes the pathologic role it can play. As indicated in this case report, efforts to control the pathologic expression of CYP27b1 include efforts to restrict bone resorption as with potent bisphosphonates such as Zometa (zoledronate), glucocorticoids such as prednisone that suppress cells often of the hematopoietic lineage such as lymphomas or macrophages that may produce 1,25(OH)~2~D in an uncontrolled fashion, and antifungal drugs such as ketoconazole that directly inhibit the CYP27b1.

3. Tissue distribution of CYP27b1 {#s0015}
=================================

[Table 1](#t0005){ref-type="table"} lists the tissues, and the cells within those tissues, in which CYP27b1 expression has been identified. The list is growing, and is likely not complete. The biologic function of CYP27b1 in many of these tissues is not clear.Table 1Tissues and cells expressing CYP27b1.Table 1A. Epithelia1. Epidermis and hair follicles (keratinocytes)2. Prostate3. Colon epithelium4. Mammary epithelium5. Uterus (endometrium)6. Corneal epithelium7. Retinal pigment epithelium8. Ciliary body epithelium9. Sinonasal epitheliumB. Placenta1. Decidua2. TrophoblastsC. Bone1. Osteoblasts2. Osteoclasts3. Osteocytes4. ChondrocytesD. Immune system1. Macrophages2. Monocytes3. Dendritic cells4. T cells5. B cellsE. Endocrine glands1. Parathyroid gland2. Pancreatic islets3. Thyroid gland4. Adrenal medulla5. Testes6. OvaryF. Other1. Brain2. Liver3. Endothelia

3.1. Epithelia {#s0020}
--------------

Epithelia form the largest group of cells that have been shown to produce 1,25(OH)~2~D~3~ and/or express CYP27b1. These cells provide the barrier between the inside environment of the body and the outside, the maintenance of which is likely one important function for CYP27b1 in these cells. The archetype cell is the epidermal keratinocyte, which we ([@bb0145]) showed over 30 years ago to be a very high expresser of CYP27b1, higher in fact than the kidney. Based on calculations from 1,25(OH)~2~D production by perfused pig skin we ([@bb0170]) determined that epidermal production of 1,25(OH)~2~D could account for all the circulating 1,25(OH)~2~D found in anephric patients (or pigs) in the basal state or after supplementation with vitamin D or 25OHD. However, most if not all 1,25(OH)~2~D produced by the epidermis is used for autocrine or paracrine purposes with little contribution to the circulation even in hyperproliferative conditions such as psoriasis in which the expression of CYP27b1 is increased ([@bb0930]). This is likely because of the rapid and extensive induction of CYP24 in these cells ([@bb0930]), which limits the amount of secreted 1,25(OH)~2~D. However, in certain dermal conditions associated with inflammatory infiltrates such as slack skin disease, a T cell lymphoproliferative disease ([@bb0535]), and subcutaneous fat necrosis of the newborn ([@bb0350]) the blood levels of calcium and 1,25(OH)~2~D increase in part due to the poorly regulated CYP27b1 activity of the inflammatory cells in the skin but not from the epidermal keratinocytes. In vitro, CYP27b1 activity as well as VDR levels decline as the keratinocytes differentiate ([@bb0775]), results consistent with observations that the highest expression of both CYP27b1 ([@bb1045]) and VDR ([@bb0705]; [@bb0920]) is found in the stratum basale, although both are found in the more differentiated layers as well. As will be discussed in the section dealing with function, 1,25(OH)~2~D plays a major role in regulating epidermal proliferation and differentiation (34)providing an effective barrier to the environment. Deletion of CYP27b1 disrupts this process ([@bb0125]).

Subsequent to these initial observations in epidermal keratinocytes, CYP27b1 expression and activity have been found in most epithelia where it has been sought. These tissues include the prostate ([@bb0505]; [@bb0230]), colonic mucosa ([@bb1045]; [@bb0100]; [@bb0955]; [@bb0180]; [@bb0610]), mammary epithelium ([@bb0855]), cervical epithelium ([@bb0400]), endometrium ([@bb0045]; [@bb1010]), various ocular barrier cells ([@bb0055]), and sinonasal epithelial cells ([@bb0925]). A common feature of these cells is their barrier function, in particular to infectious organisms, which will be discussed when their role in innate immunity is described. As in the skin when these tissues are involved in inflammatory processes CYP27b1 expression may increase, and in some cases results in the entry of 1,25(OH)~2~D into the circulation. This was well demonstrated in patients with Crohns Disease, 42% of whom had elevated serum levels of 1,25(OH)~2~D associated with increased expression of CYP27b1 in their intestinal mucosa ([@bb0005]) as well as in a mouse model of inflammatory bowel disease ([@bb0660]). Increased CYP27b1 expression relative to normal tissue is also found in endometriosis ([@bb0045]; [@bb1010]). The increased expression of CYP27b1 in these tissues is likely due to stimulation of the CYP27b1 by inflammatory cytokines, regulation that will be discussed subsequently. Although the impact of the increased CYP27b1 expression is not clear, a recent publication in which monocytes overexpressing CYP27b1 were targeted to DSS induced colitis demonstrated improvement in this mouse model ([@bb0635]), and deletion of CYP27b1 from these cells increased the susceptibility to DSS induced colitis ([@bb0660]).

Increased CYP27b1 expression is also found in the early stages of malignancy in many of these epithelia. Examples include both basal cell ([@bb0710]) and squamous cell ([@bb0800]) carcinoma, breast cancer ([@bb0855]), colon cancer ([@bb0100]; [@bb0955]; [@bb0735]), prostate cancer (although malignancy appears to reduce CYP27b1 expression and activity in these cells) ([@bb0505]; [@bb0230]), cervical cancer ([@bb0400]), lung cancer ([@bb1040]; [@bb0685]), and endometrial cancer ([@bb0110]). This observation suggests a role for CYP27b1 in regulating proliferation and differentiation of these tissues, reducing tumor progression (prostate cancer being a possible exception). Support for this concept comes from a recent study in which CYP27b1 was deleted from cells of a breast cancer model, resulting in acceleration of tumorigenesis ([@bb0640]). However, these cancers are also associated with alternatively spliced forms of CYP27b1, which may have less or no 1α hydroxylase activity and may block that of intact CYP27b1 as has been shown in proximal tubule cells ([@bb1030]). Such alternatively spliced forms have been demonstrated in breast ([@bb0250]; [@bb0360]), endometrium ([@bb0110]), keratinocytes ([@bb0860]), lung ([@bb0790]), and cervix ([@bb0790]; [@bb0405]). Moreover, the increase in CYP27b1 is often accompanied by an increase in CYP24A1, which would counter the increased endogenous production of 1,25(OH)~2~D as shown in breast cancer ([@bb0965]), colon cancer ([@bb0100]), lung cancer ([@bb0515]), and endometrial cancer ([@bb0045]). As tumors become less differentiated their CYP27b1 expression generally decreases ([@bb0100]). This has been associated with increased promoter hypermethylation of CYP27b1 in a substantial number of breast cancers ([@bb0870]) and prostate tumors ([@bb0555]). Other studies suggest that the CYP27b1 promoter is down regulated by NFκB ([@bb0835]) ([@bb0325]), the expression of which is increased in many cancers surrounded by an inflammatory infiltrate ([@bb0965]).

3.2. Placenta {#s0025}
-------------

As noted previously, the placenta was the first clearly identified extra renal source of 1,25(OH)~2~D production. CYP27b1 is expressed in both the maternal decidual stromal cells and the fetal trophoblasts ([@bb1020]; [@bb1045]; [@bb0285]; [@bb0295]; [@bb1055]). During pregnancy the rise in maternal 1,25(OH)~2~D levels is due to production by the maternal portion of the placenta, as 1,25(OH)~2~D, unlike 25OHD, does not readily cross the placenta. This was well demonstrated in a study of Hannover pigs which lack a functional CYP27b1. During pregnancy there was no rise in serum 1,25(OH)~2~D despite heterozygote fetuses ([@bb0590]), which are capable of producing their own 1,25(OH)~2~D ([@bb1025]). CYP27b1 expression increases during early pregnancy in both the trophoblasts and decidua, but not the endometrium ([@bb1010]; [@bb0340]). Unlike most tissues the rise in CYP27b1 expression is not accompanied by an increased expression of CYP24a1 ([@bb0340]), which actually shows an increase in methylation of its promoter ([@bb0725]), presumably suppressing its expression. Deletion of CYP27b1 is associated with uterine hypoplasia and infertility in female mice ([@bb0750]). Preeclampsia, a condition developing mid pregnancy and marked by hypertension is associated with a reduction in serum 1,25(OH)~2~D. Trophoblasts taken from preeclamptic placentae show decreased CYP27b1 activity and response to IGF1, which is also reduced in these patients ([@bb0300]). However, other investigators observed an increase in CYP27b1 expression in preeclamptic placentae ([@bb0365]), suggesting a disparity between mRNA levels and function of the protein product as would happen if the increase in mRNA represented alternatively spliced forms of CYP27b1.

3.3. Bone {#s0030}
---------

Bone cells were the next cell type to be identified as expressing CYP27b1 ([@bb0970]). The importance of this observation remained ignored for decades as the prevailing dogma was that vitamin D signaling in bone was minimal at best, in that the rickets of the CYP27b1 and *Vdr* knockouts could be corrected with a diet high in calcium and phosphate ([@bb0270]; [@bb0060]). However, a more extensive evaluation of the skeleton of these knockouts individually and in combination demonstrated that even when hypocalcemia and secondary hyperparathyroidism are prevented by the rescue diet not all changes in osteoblast number, mineral apposition rate and bone volume are rescued ([@bb0760]). In particular, the width of the growth plate remained increased in the *Cyp27b1* knockout and double knockout of both *Cyp27b1* and Vdr, the trabecular bone was markedly osteopenic with decreased mineral apposition rates in both cortical and trabecular bone, and alkaline phosphatase expression was reduced, all signifying decreased osteoblast number or activity. Osteoclast numbers in the trabeculae were likewise reduced as was expression of Rankl. In vitro, bone marrow stromal cell (BMSC) cultures from these animals demonstrated reductions in colony forming units and mineralized nodules. Such findings stimulated a reexamination of the role of Cyp27b1 in bone. Cyp27b1 is expressed in all bone cell types including chondrocytes ([@bb0765]; [@bb0755]), mesenchymal stem cells (MSC) (osteoprogenitors from bone) ([@bb1070]; [@bb0440]), osteoblasts ([@bb0310]; [@bb0070]), osteoclasts ([@bb0565]), and possibly osteocytes (shown in an osteocyte cell line MLO-A5) ([@bb0985]). The endogenously produced 1,25(OH)~2~D when these cells are treated with 25OHD stimulates their differentiation, and in the case of the MSC blocks their differentiation. Knockdown of Cyp27b1 with siRNA in MSC and osteoblasts blocked the ability of 25OHD to induce their differentiation ([@bb0440]; [@bb0070]). However, although 25OHD stimulated osteoclast differentiation from peripheral blood mononuclear cells (PBMC), it reduced the resorptive activity of the osteoclasts that formed. On the other hand, when splenocytes were used as the source of osteoclast progenitors, cells from CYP27b1 knockout animals were fewer and smaller but on a per cell basis had increased resorptive capacity ([@bb0805]). Similar findings had been shown for *Vdr* knockout splenocytes ([@bb0565]). The cell specific deletion of *Cyp27b1* from chondrocytes shows a reduction in osteoclastogenesis in the primary spongiosa associated with decreased Rankl expression, an increase in trabecular bone volume in the metaphysis of neonatal long bones, and a reduction in angiogenesis associated with a reduction in Vegf expression. The width of the hypertrophic zone of the growth plate was widened on embryonic day 15.5, but these changes in the growth plate did not persist ([@bb0905]; [@bb0720]). Some of these changes may have been secondary to the increase in circulating Fgf23 in these mice ([@bb0905]). When Cyp27b1 was overexpressed in chondrocytes the opposite effects to that of the knockout were observed ([@bb0720]).

3.4. Cells of the immune system {#s0035}
-------------------------------

Although sarcoid tissue was clearly identified as the extrarenal source of 1,25(OH)~2~D in 1981 ([@bb0095]), the pulmonary alveolar macrophage from patents with sarcoidosis 1983 was perhaps the clearest demonstration that the macrophage was responsible ([@bb0020]). Unlike the kidney, the production of 1,25(OH)~2~D by macrophages was substrate dependent ([@bb0020]) and not product limited ([@bb0010]), and the CYP27b1 activity in macrophages was clearly not regulated by PTH and calcium ([@bb0510]). Part of the lack of regulation is due to truncated versions of CYP24a1 which do not have enzymatic activity and so do not catabolize 1,25(OH)~2~D within the macrophage allowing it to enter the circulation ([@bb0810]). This truncated form of CYP24a1, which includes the substrate binding domain but not the mitochondrial targeting sequence, is postulated to act as a dominant negative form of CYP24a1, binding 1,25(OH)~2~D within the cytoplasm and preventing its catabolism ([@bb0810]). Both intact CYP24a1 and the truncated variant are induced in macrophage cell lines (HD-11 and THP-1), but CYP24a1 activity is not increased. As mentioned earlier, at least in the placenta the expression of CYP24a1 does not increase in parallel with the increase in CYP27b1 due to methylation (and inhibition) of its promoter, possibly also contributing to the decreased regulation of 1,25(OH)~2~D production by these cells ([@bb0725]).

Extrarenal CYP27b1 expression in macrophages is not limited to sarcoidosis. CYP27b1 expression has been found in pulmonary alveolar macrophages from patients with tuberculosis ([@bb0105]), coccidiomycosis and cryptococcosis ([@bb0050]), the peritoneum from individuals undergoing peritoneal dialysis ([@bb0075]) and from patients with peritonitis ([@bb0475]), from the synovium of patients with inflammatory arthritis ([@bb0480]), granulomata in the colon of patients with Crohn\'s disease ([@bb0005]), granulomata in the skin of a patient with slack skin disease (a T cell lymphoproliferative disorder ([@bb0535])), subcutaneous fat necrosis of the newborn ([@bb0350]; [@bb0355]), granulomata within lymph nodes ([@bb1045]), circulating monocytes from patients with chronic renal failure ([@bb0320]), foreign body granulomata ([@bb0490]) and normal monocytes activated in vitro ([@bb0465]). Kallas and Hewison provide a well referenced table of these infectious and inflammatory causes of elevated 1,25(OH)~2~D production ([@bb0530]).

Dendritic cells (DC) require activation to express CYP27b1 ([@bb0410]). These are the principal antigen presenting cells to the T cells, a key feature of adaptive immunity. 1,25(OH)~2~D suppresses the maturation of DC and increases their expression of IL-10 that together increase tolerogenesis with reduction of the differentiation of Th1 and Th17 lymphocytes and increased differentiation of Th2 and Treg lymphocytes ([@bb0770]). Th lymphocytes also express CYP27b1 as well as the VDR when activated ([@bb0885]; [@bb0115]). 1,25(OH)~2~D inhibits the proliferation of these cells as well as their production of cytokines such as IL-2, IFNγ, and TNF, while promoting the expression of Th2 and Treg cytokines such as IL-3, IL-4, IL-5, and IL-10 ([@bb0620]; [@bb0200]). B lymphocytes also express CYP27b1 ([@bb0235]). 1,25(OH)~2~D reduced their proliferation and differentiation into plasma cells thus reducing antibody production ([@bb0235]). The role of endogenous 1,25(OH)~2~D production in T and B cells was recently tested by examining the response of these cells to OVA induced sensitization and intestinal infection with *Heligmosomoides polygyrus*, two means of inducing an IgE and IgG1 response ([@bb0645]). In the global CYP27b1 knockout, IgE and IgG1 were increased more than controls in the OVA-sensitization model, but only IgE in the *Heligmosomoides polygyrus* model. When CYP27b1 was selectively deleted in either the T or B lymphocytes significant increases in IgE and antibody secreting cells after OVA challenge were seen only in the T cell specific knockout.

3.5. Endocrine glands {#s0040}
---------------------

Several endocrine glands, the parathyroid gland and pancreatic islets in particular, whose products are regulated by 1,25(OH)~2~D~,~ also express CYP27b1 ([@bb1045]; [@bb0185]; [@bb0255]; [@bb0825]; [@bb0820]). Expression of CYP27b1 appears to be greater in parathyroid adenomas, whether primary or secondary to renal failure, compared to normal glands ([@bb0255]; [@bb0850]), and is preferentially expressed in oxyphil compared to chief cells ([@bb0825]). When sequenced, none of these adenomas expressed inactivating mutations in CYP27b1 to suggest that CYP27b1 was functioning as a tumor suppressor gene ([@bb0605]). Malignant pancreatic tissue and cell lines derived from such tissue express CYP27b1 at levels comparable to normal tissue ([@bb0845]). Polymorphisms in CYP27b1 have been associated with increased risk of type 1 diabetes mellitus ([@bb0085]), although it is unclear whether this link is due to regulation of insulin secretion or to the immune response leading to this form of diabetes. The thyroid has also been shown to express CYP27b1 ([@bb0245]), and this expression is increased in papillary carcinoma of this gland ([@bb0550]), although CYP27b1 expression is decreased in metastases ([@bb0245]). However, unlike the parathyroid gland and pancreatic islet, it is unclear whether 1,25(OH)~2~D influences hormone secretion from the thyroid gland. CYP27b1 protein has been detected in the adrenal medulla by immunohistochemistry ([@bb1050]), although no reports of 1,25(OH)~2~D~3~ regulated cathecholamine production or altered CYP27b1 expression in patients with pheochromocytoma have been published. The testes express CYP27b1 ([@bb0415]). Using the promoter of CYP27b1 to drive a luciferase promoter, Anderson et al. ([@bb0065]) localized CYP27b1 expression in both Leydig and Sertoli cells of the testes, results subsequently confirmed ([@bb0195]). CYP27b1 expression has also been found in the ovary ([@bb0345]) and ovarian cancer ([@bb0370]; [@bb0210]) where its expression is negatively correlated with tumor growth. Dysgerminomas of the ovary have a much greater expression of CYP27b1 than normal ovarian tissue ([@bb0345]). This has significance in that hypercalcemia is known to occur with dysgerminomas, and a recent case report attributed the hypercalcemia to increased 1,25(OH)~2~D levels in a patient with an ovarian dysgerminoma ([@bb0485]).

3.6. Other tissues {#s0045}
------------------

The liver, well known to be the major site for 25OHD production, has also been shown to express CYP27b1 ([@bb0500]), which at least in the rat appears to disappear postnatally ([@bb0940]). This observation has received little further investigation following these initial and early publications.

Expression of CYP27b1 in the brain was also a surprise result of our initial tissue screen for CYP27b1 ([@bb0415]). Subsequent localization studies have demonstrated expression in the cerebellum and cerebral cortex ([@bb1045]), and, in particular, in Purkinje cells ([@bb0065]). Glioblastomas show increased CYP27b1 expression ([@bb0375]) along with spliced variants of CYP27b1 ([@bb0675]), the significance of which is uncertain ([@bb0305]). Zehnder et al. observed CYP27b1 expression in human endothelial cells and 1,25(OH)~2~D production by human umbilical vein endothelial cells in vitro ([@bb1060]). 25OHD or 1,25(OH)~2~D decreased their proliferation and increased adhesion of the monocyte cell like U937 to these cells suggesting a role in endothelial cell adhesion.

4. Regulation of extrarenal CYP27b1 expression {#s0050}
==============================================

An important feature of extrarenal CYP27b1 is that its regulation differs from that of the kidney, the regulation of CYP27b1 in the proximal convoluted tubule (PCT) of the kidney to be precise. CYP27b1 in the renal PCT is controlled principally by three hormones, parathyroid hormone (PTH), FGF23, and 1,25(OH)~2~D itself responding at least in part to changes in ambient calcium and phosphate levels (review in ([@bb0520])). Calcitonin regulates CYP27b1 activity in the proximal straight tubule ([@bb0540]), but this has received little further study. PTH stimulates CYP27b1 expression principally by acting on its membrane receptor to promote cyclic AMP formation, PKA activation, and enhanced binding of CCAAT box binding protein to its proximal response element in the CYP27b1 promoter ([@bb0420]). FGF23 inhibits CYP27b1 expression by a mechanism involving its binding to one of several FGF receptors in association with Klotho, activating MAPK, but the molecular events leading to inhibition of CYP27b1 expression by this pathway are not well defined ([@bb0915]). Calcium and phosphate, by regulating the secretion of PTH and FGF23 from the parathyroid glands and bone, respectively, indirectly regulate CYP27b1 activity in the kidney, although they also have direct effects ([@bb0740]; [@bb0950]; [@bb0120]). 1,25(OH)~2~D directly inhibits CYP27b1 expression in the kidney through a complex mechanism involving VDR that brings both histone deacetylases (HDAC) and DNA methyl transferases to the promoter of CYP27b1 inhibiting its transcription ([@bb0560]). These feedback loops provide very tight regulation of 1,25(OH)~2~D production by the PCT of the kidney, control that differs from that of CYP27b1 in other cell types including that of distal renal tubule cells where PTH has little effect ([@bb0090]). [@bb0700] recently identified a region in the CYP27b1 enhancer region in DNA from the kidney that was responsive to PTH, FGF23, and 1,25(OH)~2~D regulation. However, this region was not accessible to such regulation in the extrarenal tissues they tested including skin and bone, but was regulated by inflammatory factors, consistent with different regulatory mechanisms in extra renal tissues. However, this distinction is not so precise as the genomic data would suggest when tested directly in cells from non-renal tissues as we will now describe.

4.1. Keratinocytes {#s0055}
------------------

When we ([@bb0150]) first examined the ability of PTH to stimulate 1,25(OH)~2~D production by keratinocytes, we observed that their response to PTH differed from that of the kidney in that PTH binding to a receptor could not be demonstrated, and cyclic AMP did not appear to be involved, although the response was potentiated by inhibition of phosphodiesterase. Moreover, Flanagan et al. ([@bb0380]) using a CYP27b1 promoter/luciferase reporter assay demonstrated PTH stimulated expression in a kidney cell line but not in keratinocytes, suggesting that the effect of PTH may be post-transcriptional. However, this construct consisted of only 1500 bp 5′ of the promoter, and may not have contained the region of DNA that responded to PTH signaling in keratinocytes. PTH/PTHrP receptors have subsequently been identified in the epidermis and isolated keratinocytes ([@bb0335]), and Muehleisen et al. ([@bb0715]) more recently made the surprising observation that incubation of keratinocytes with 25OHD could induce the expression of the PTH/PTHrP receptor. Moreover, epidermal keratinocytes produce PTHrP ([@bb0695]), so conceivably keratinocyte CYP27b1 is regulated by PTH/PTHrP, but this has not yet been demonstrated. Likewise, the effect of FGF23 on keratinocyte CYP27b1 expression or function has not been reported. Unlike the kidney, 1,25(OH)~2~D does not directly affect CYP27b1 expression in keratinocytes. Rather, 1,25(OH)~2~D regulates its own levels in the keratinocyte by inducing CYP24a1, the catabolic enzyme for 1,25(OH)~2~D ([@bb1035]). Tumor necrosis factor-α (TNF) ([@bb0165]) and interferon-γ (IFN) ([@bb0160]), on the other hand, are potent inducers of CYP27b1 activity in the keratinocyte as is TGFβ1 ([@bb0840]). 1,25(OH)~2~D induces the expression TLR2 and CD14, and activation of TLR2 with a specific agonist, malp-2, but not with a TLR 4 agonist, lipopolysaccharide (LPS), induces CYP27b1 ([@bb0840]). This feed forward mechanism plays a role in both wound healing and the response to infection as will be discussed subsequently.

4.2. Bone {#s0060}
---------

CYP27b1 in human mesenchymal stem cells from bone marrow is stimulated by PTH through mechanisms involving both the phosphorylation of CREB (an acute response) and through the expression of IGF1 and the activation of its receptor (longer term response) ([@bb0445]). 25OHD increases CYP27b1 expression in these cells, but that appears to be due to a combination of increased expression of the PTH/PTHrP receptor ([@bb1075]) and IGF1 ([@bb1070]) as 1,25(OH)~2~D decreases the expression of CYP27b1 in these cells ([@bb1070]). Similarly, PTH stimulated osteoblasts from human bone explants ([@bb0895]), although no mechanism was evaluated. In contrast to these results others have not found that PTH stimulated CYP27b1 in human osteoblasts ([@bb0310]) or in ROS 17/2.8 osteoblasts transfected with a 1500 bp 5′ flanking region of CYP27b1 ([@bb0980]). Moreover, in the latter studies the authors observed a 50+ % inhibition by IGF1 and TGF-β with no inhibition by 1,25(OH)~2~D. However, as mentioned above, the enhancer regions regulating a gene may be at substantial distances from the promoter, so that such studies with short constructs may be misleading.

4.3. Macrophages and monocytes {#s0065}
------------------------------

The production of 1,25(OH)~2~D by pulmonary alveolar macrophages is activated by IFNγ and TNFα, but not by IFNα and IFNβ, and is inhibited by dexamethasone ([@bb0010]; [@bb0785]) ([@bb0010]). The stimulation of CYP27b1 by IFNγ may involve increased NO production ([@bb0025]). Preincubation of these cells with 1,25(OH)~2~D did not alter enzymatic activity indicating no direct inhibition as in the kidney ([@bb0010]). IL-1, IL-2 and IL-15 also stimulate CYP27b1 activity in peripheral blood mononuclear cells (PBMC), whereas IL-4 is suppressive ([@bb0465]; [@bb0330]). In contrast to Th1 cells, which produce IFNγ and IL-2, Th2 cells produce not only IL-4 but IFNβ that increases IL-10 to decrease CYP27b1 activity ([@bb0960]). In other studies of PBMC, the combination of IFNγ and either phorbol ester (PMA) or LPS induced CYP27b1 ([@bb0910]). In these studies of PBMC the induction of CYP27b1 was blocked by inhibition of the JAK/STAT pathway, NFκB pathway, and p38 MAPK pathway ([@bb0910]). The same group then demonstrated in peritoneal macrophages (PM) that IFNγ stimulation of CYP27b1 required C/EBPβ and was inhibited by knocking out STAT1α or Interferon regulatory factor 1 (IRF1). LPS stimulates these pathways through TLR4 in association with the coreceptor CD14 ([@bb0910]), a point that will become important when the functional role of extra renal production of 1,25(OH)~2~D~3~ is discussed, and a difference from the role of TLR2 in keratinocytes ([@bb1000]). Similar results were obtained with the macrophage cell line THP-1 ([@bb0745]). In a v myc transformed myelomonocytic cell line (HD-11), [@bb0030] demonstrated stimulation of 1,25(OH)~2~D production by LPS and IFNγ, and failure of PTH or calcium and phosphate to regulate CYP27b1 activity. Both PBMC and PM express FGF receptors and Klotho, and respond to FGF23 with a reduction in CYP27b1 expression likely through the MAPK pathway similar to that in the kidney ([@bb0075]).

4.4. Parathyroid gland {#s0070}
----------------------

The parathyroid gland expresses both FGF receptors and Klotho ([@bb0890]). Unlike the kidney, FGF23 stimulates CYP27b1 expression in the parathyroid gland ([@bb0825]; [@bb0585]). Activation of the calcium sensing receptor in the parathyroid gland either by calcium or cinacalcet also increases CYP27b1 expression (112). Both FGF23 ([@bb0890]) and cincalcet ([@bb0825]) reduce PTH secretion suggesting a link between PTH secretion and CYP27b1 expression. However, as yet unpublished observations by Chang et al. have shown that PTH stimulates CYP27b1 activity just as parathyroid gland specific knockout of CYP27b1 markedly increases PTH secretion (Chang et al., personal communication) indicating an intracrine feedback loop in the parathyroid gland between PTH and CYP27b1.

5. Function of extra renal CYP27b1 {#s0075}
==================================

The kidney appears to be the major if not the sole source of circulating 1,25(OH)~2~D, so the role of extrarenal CYP27b1 needs to be addressed. Two considerations come to mind. First the substrate for CYP27b1, namely 25OHD, circulates at much higher concentrations than 1,25(OH)~2~D. Although essentially all of the 25OHD is protein bound (99.97%) ([@bb0155]), some cells express a mechanism involving megalin/cubilin that enables them to transport the 25OHD bound to its major carrier vitamin D binding protein (DBP) into the cell ([@bb0730]). This was originally discovered in the kidney, enabling the kidney to recover DBP bound 25OHD from the glomerular filtrate, but megalin/cubilin expression has also been observed in a wide number of tissues including the placenta, parathyroid gland, choroid plexus, thyroid, intestinal epithelium, endometrium, epididymis (reviewed in ([@bb0240])), macrophages ([@bb0035]) and osteoblasts ([@bb0070]). However, demonstration of uptake of DBP bound 25OHD by these cells has not been established in most cases. Second, circulating 1,25(OH)~2~D levels are tightly controlled, whereas the extrarenal CYP27b1 production operates under different controls and so may be more adaptable to the specific needs of that particular cell. That said the roles of extrarenal CYP27b1 can be considered to fall into three broad categories: the regulation of cellular proliferation and differentiation, the regulation of hormone secretion, and the regulation of immune function both innate and adaptive. These are not mutually exclusive. In all cases the role of endogenously produced 1,25(OH)~2~D is that of a ligand for the vitamin D receptor (VDR) expressed in nearly every cell in the body.

5.1. Regulation of proliferation and differentiation {#s0080}
----------------------------------------------------

Epidermal keratinocytes provide an excellent model to evaluate the ability of 1,25(OH)~2~D to regulate proliferation and differentiation in a normal cell. 1,25(OH)~2~D promotes the differentiation of keratinocytes while inhibiting their proliferation ([@bb0140]; [@bb0130]). In the epidermis proliferation occurs in the basal layer, and as the keratinocytes move out of the basal layer differentiation is initiated. As the keratinocytes move from one layer of epidermis to the next, differentiation proceeds in a sequential fashion ultimately resulting in the enucleated corneocyte enmeshed in a lipid rich matrix that provides the barrier function. 1,25(OH)~2~D is involved in all steps of this process in that it limits proliferation in the basal layer while inducing in a sequential pattern the expression of genes whose products ultimately produce the permeability barrier. Included in the development of the permeability barrier is the production of antimicrobial peptides such as cathelicidin, important for the innate immune response in the epidermis ([@bb0840]) and other epithelial and immune cells as will be discussed. CYP27b1 like VDR is found throughout the epidermis, although expression appears to be higher in the basal layer of the epidermis ([@bb1045]; [@bb0705]; [@bb0920]). The CYP27b1 null mouse has increased keratinocyte proliferation, decreased epidermal differentiation, fails to form the calcium gradient within the epidermis important for the differentiation process, and is limited in the ability to reform the permeability barrier following disruption ([@bb0175]). Moreover, these mice are less resistant to infection ([@bb0715]) and have a blunted innate immune response to wounding ([@bb0840]).

### 5.1.1. Psoriasis {#s0085}

Psoriasis is an example of a hyperproliferative disease of the skin for which analogs of 1,25(OH)~2~D and 1,25(OH)~2~D itself have proven successful ([@bb0215]). Psoriasis is a chronic, generalized, and scaly erythematous dermatosis thought to be due to a Th1 or Th17 mediated immune reaction to as yet unidentified antigens in the skin that may cause or at least is accompanied by increased proliferation and decreased differentiation of the keratinocytes in the epidermis. 1,25(OH)~2~D and its analogs likely work by inhibiting the inflammatory component of the disease via a direct action on the T cells ([@bb0080]) as well as by reducing keratinocyte proliferation and enhancing their differentiation ([@bb0580]). Given the increased expression of CYP27b1 in these cells, topical treatment with 25OHD may also prove effective, but to my knowledge results with this form of therapy have not been reported.

### 5.1.2. Cancer {#s0090}

As noted in the section on tissue distribution CYP27b1 is expressed in a number of malignant tissues. Moreover, expression is often increased in the early stages of tumor development but is lost as the tumors dedifferentiate ([@bb0495]). Many animal studies have demonstrated a reduction in growth in such cancers following administration of 1,25(OH)~2~D or its analogs ([@bb0220]), and epidemiologic evidence is consistent with a role for vitamin D in preventing many of these cancers in humans ([@bb0430]; [@bb0205]; [@bb0545]; [@bb0435]; [@bb0470]). Moreover, polymorphisms in CYP27b1 have been found in hepatocellular carcinoma ([@bb0600]), lung cancer ([@bb0575]), and prostate cancer ([@bb0450]). In a recent study Li et al. ([@bb0640]) deleted CYP27b1 from the mammary epithelium in a mouse breast cancer model and demonstrated an acceleration of tumorigenesis. However, in the CYP27b1 null mouse we were unable to demonstrate an increase in UV induced tumor formation using a protocol comparable to that which induced tumors in VDR null mice ([@bb0135]). Therefore, the role of extrarenal CYP27b1 in tumor development may be tissue specific.

5.2. Regulation of hormone secretion {#s0095}
------------------------------------

### 5.2.1. Parathyroid hormone (PTH) {#s0100}

Circulating PTH levels are better correlated with 25OHD levels than with 1,25(OH)~2~D levels ([@bb1005]) even though it is 1,25(OH)~2~D that inhibits the synthesis and secretion of PTH ([@bb0290]) and prevents the proliferation of the parathyroid gland ([@bb0290]; [@bb0680]). The expression of CYP27b1 within the parathyroid gland could account for this observation. The parathyroid gene contains a negative VDRE through which 1,25(OH)~2~D exerts its suppression ([@bb0290]). 1,25(OH)~2~D also induces the calcium sensing receptor (CaSR) in the parathyroid gland ([@bb0225]), which sensitizes the parathyroid gland to calcium inhibition. As noted previously Cheng et al. in studies reported only in abstract form (ASBMR, 2011) have shown that deletion of CYP27b1 from the parathyroid gland markedly increased PTH secretion.

### 5.2.2. Insulin {#s0105}

A number of mostly case control and observational studies have suggested that vitamin D deficiency contributes to increased risk for types 1 and 2 diabetes mellitus ([@bb0780]). In animal studies 1,25(OH)~2~D has been shown to stimulate insulin secretion, although the mechanism is not well defined ([@bb0525]; [@bb0615]). Moreover, a recent study identified a polymorphism in CYP27b1 that predisposed to islet cell autoimmunity ([@bb0395]). However, it is not clear what role the CYP27b1 in the pancreatic islet plays in this process as diabetes mellitus is not described in the *Cyp27b1* knockout. This question will be best answered with tissue specific *Cyp27b1* deletion.

### 5.2.3. Renin {#s0110}

The renin/angiotensin system is active in both heart and kidney. It is a major regulator of blood pressure. 1,25(OH)~2~D is a negative regulator of renin secretion ([@bb0630]). The *Cyp27b1* knockout mouse develops hypertension and cardiac hypertrophy with increased expression of the renin/angiotensin system in both heart and kidney. These changes persisted even when the mice were placed on the rescue diet to normalize their calcium, phosphate and PTH levels ([@bb1065]). Although cardiac specific deletion of VDR has been reported showing similar cardiac changes ([@bb0425]), comparable studies have not been reported with a cardiac specific *Cyp27b1* knockout.

### 5.2.4. Fibroblast growth factor 23 (FGF23) {#s0115}

FGF23 is produced primarily in bone by osteoblasts and osteocytes. 1,25(OH)~2~D stimulates this process, but the mechanism is not clear ([@bb0570]). Surprisingly, chondrocyte specific deletion of *Cyp27b1* reduced circulating levels of Fgf23 presumably altering an as yet unidentified signal, possibly 1,25(OH)~2~D itself, from chondrocytes to the osteoblasts/osteocytes. At this point, osteoblast/osteocyte specific *Cyp27b1* deletions have not been reported.

### 5.2.5. Estrogen and testosterone {#s0120}

1,25(OH)~2~D regulates the expression of aromatase involved in estrogen metabolism in mammary tumors potentially contributing to their antiproliferative actions ([@bb0935]). However, the impact of 1,25(OH)~2~D on ovarian production of estrogen has not been reported. 1,25(OH)~2~D does not alter testosterone production in the testes ([@bb0190]). Female mice lacking Cyp27b1 are infertile with hypoplastic uteri and loss of corpora lutea suggesting estrogen deficiency, but estrogen levels were not measured ([@bb0750]). Male mice lacking Cyp27b1 remain fertile.

5.3. Regulation of immune function {#s0125}
----------------------------------

### 5.3.1. Adaptive immunity {#s0130}

The adaptive immune response involves the ability of T and B lymphocytes to produce cytokines and immunoglobulins, respectively, to specifically combat the source of the antigen presented to them by cells such as macrophages and dendritic cells. As noted previously, CYP27b1 expression is increased when these cells are activated. 1,25(OH)~2~D exerts an inhibitory action on the adaptive immune system by suppressing the proliferation and differentiation of B-cell precursors into plasma cells ([@bb0235]), inhibiting T cell proliferation and function ([@bb0815]), in particular Th1 ([@bb0625]) and Th17 ([@bb0260]) cells, and shifting the balance to favor Th2 cell ([@bb0200]) and regulatory T cell (Treg) function. At least in part these actions on T cell proliferation and differentiation stem from actions of 1,25(OH)~2~D on dendritic cells to reduce their antigen presenting capability. The ability of 1,25(OH)~2~D to suppress the adaptive immune system appears to be beneficial for a number of conditions in which the immune system is directed at self---i.e. autoimmunity. In a number of experimental models ([@bb0040]; [@bb0280]) including inflammatory arthritis, autoimmune diabetes, experimental allergic encephalitis (a model for multiple sclerosis), and inflammatory bowel disease 1,25(OH)~2~D administration has prevented and/or treated the disease process. Thus local production of 1,25(OH)~2~D in pulmonary alveolar macrophages, peritoneal macrophages, synovial macrophages, PBMC, pancreatic islets, neurons in the brain, lung, and intestinal mucosa, all tissues which express CYP27b1, may provide a mechanism to control the destructive immune process that is the etiology for these disease processes.

### 5.3.2. Innate immunity {#s0135}

Innate immune responses involve the activation of toll-like receptors (TLRs) in a number of epithelial cells including those of the epidermis, gingiva, intestine, vagina, placenta, bladder and lungs as well as cells of the immune system including PBMC and macrophages. TLRs are transmembrane pathogen-recognition receptors that interact with specific membrane patterns (PAMP) shed by infectious agents that trigger the innate immune response in the host ([@bb0690]). Activation of TLRs leads to the induction of antimicrobial peptides and reactive oxygen species, which kill the organism. Among those antimicrobial peptides is cathelicidin. The expression of this antimicrobial peptide is induced by 1,25(OH)~2~D in both myeloid and epithelial cells ([@bb0455]; [@bb1015]), cells which express both VDR and CYP27b1. The innate immune response of the macrophage, keratinocyte, and placenta provide the best examples of the role of local CYP27b1 activity to meet a local challenge. Vitamin D deficiency has long been associated with increased risk of tuberculosis ([@bb0990]), and 1,25(OH)~2~D has long been recognized to potentiate the killing of mycobacteria by monocytes ([@bb0830]). Macrophages when activated by mycobacterial lipopeptides through TLR2/1 heterodimers express both CYP27b1 and VDR, leading to the production of 1,25(OH)~2~D from circulating 25OHD, which bound to VDR to induce cathelicidin that enhanced killing of the mycobacterium ([@bb0655]). Inadequate circulating 25OHD levels failed to support this process ([@bb0655]). In keratinocytes the expression of TLR2 and CD14, critical receptors for a number of pathogenic organisms activating the innate immune response, is increased by 1,25(OH)~2~D as is the expression of cathelicidin ([@bb0840]). When the skin is wounded expression of CYP27b1 increases along with that of TLR2, CD14, and cathelicidin ([@bb0840]). These changes do not occur in mice lacking Cyp27b1 in their epidermis ([@bb0840]). In the placenta both the maternal decidua and fetal trophoblast produce cathelicidin in response to 1,25(OH)~2~D ([@bb0665]). When the placentas from *Cyp27b1* knockout mice were evaluated, inflammatory cytokine production in response to LPS was amplified suggesting an important role for CYP27b1 in this tissue controlling the placental response to inflammatory stimuli ([@bb0670]). Other epithelia of tissues facing the outside environment must provide a protective barrier, and it is anticipated that the innate immune system in these tissues will likewise be regulated by local 1,25(OH)~2~D production. However, this needs to be demonstrated with tissue specific deletion of *Cyp27b1*.

6. Summary {#s0140}
==========

CYP27b1 is expressed widely and in cells also expressing VDR. Although the data are limited with respect to tissue specific deletions of CYP27b1, in those tissues where this has been achieved local production of 1,25(OH)~2~D has been shown to exert effects on that tissue independent of circulating 1,25(OH)~2~D. However, such studies are the exception and not the rule, so that definitive data on this point will only come from additional studies with tissue specific deletion of CYP27b1. Should local expression of CYP27b1 be shown as critical for cell specific functions, the potential to manipulate 1,25(OH)~2~D production in the tissue of choice without incurring systemic changes in calcium homeostasis will be an important advance in the treatment of a variety of diseases. These include treatment of cancers with uncontrolled proliferation and disordered differentiation, better management of hyperparathyroidism and insulin secretion in diabetics, suppressing renin/angiotension in hypertension, improving wound repair, limiting tissue destruction in autoimmune diseases, and enhancing the resistance to infectious organisms such as streptococcus and tuberculosis.
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